Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China

Enzon Pharmaceuticals, Inc. ENZN and Zhejiang Hisun Pharmaceuticals Co announced today a long-term strategic research, development and licensing collaboration. The agreement provides for the research and development of therapeutics using Enzon's customized PEGylation linker technology. The agreement also includes the license to Hisun of development and commercialization rights for Enzon's PEG-SN38 (EZN-2208), a novel, Phase II PEGylated version of SN38, in the territory of China.